BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Valencia
About this trial
1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion
Eligibility criteria
Qualifiers
Adults aged 18 years and older at the time of enrollment. There is no upper age limit to ensure inclusivity across age ranges.
A confirmed diagnosis of Idiopathic Intracranial Hypertension, established according to the Dandy criteria.
The diagnostic process must exclude other potential causes of increased intracranial pressure as detailed in the 'Diagnosis' section, ensuring an accurate identification of idiopathic cases.
Disqualifiers
A diagnosis other than IIH, specifically: tension-type headache, Chiari I malformation, or any other headache disorder unrelated to IIH.
The presence of secondary causes of increased intracranial pressure (e.g., structural brain abnormalities, venous sinus thrombosis, or medication-induced factors).
Trial design
Treatments tested in this trial
- Weight loss without pharmacotherapy
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov